Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2010 1
2011 1
2012 1
2014 1
2016 2
2021 6
2022 8
2023 6
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Results by year

Filters applied: . Clear all
Page 1
Tumor Fraction Correlates With Detection of Actionable Variants Across > 23,000 Circulating Tumor DNA Samples.
Husain H, Pavlick DC, Fendler BJ, Madison RW, Decker B, Gjoerup O, Parachoniak CA, McLaughlin-Drubin M, Erlich RL, Schrock AB, Frampton GM, Das Thakur M, Oxnard GR, Tukachinsky H. Husain H, et al. Among authors: tukachinsky h. JCO Precis Oncol. 2022 Oct;6:e2200261. doi: 10.1200/PO.22.00261. JCO Precis Oncol. 2022. PMID: 36265119 Free PMC article.
Unique Spectrum of Activating BRAF Alterations in Prostate Cancer.
Chehrazi-Raffle A, Tukachinsky H, Toye E, Sivakumar S, Schrock AB, Bergom HE, Ebrahimi H, Pal S, Dorff T, Agarwal N, Mahal BA, Oxnard GR, Hwang J, Antonarakis ES. Chehrazi-Raffle A, et al. Among authors: tukachinsky h. Clin Cancer Res. 2023 Oct 2;29(19):3948-3957. doi: 10.1158/1078-0432.CCR-23-1393. Clin Cancer Res. 2023. PMID: 37477913 Free PMC article.
Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types.
Kasi PM, Lee JK, Pasquina LW, Decker B, Vanden Borre P, Pavlick DC, Allen JM, Parachoniak C, Quintanilha JCF, Graf RP, Schrock AB, Oxnard GR, Lovly CM, Tukachinsky H, Subbiah V. Kasi PM, et al. Among authors: tukachinsky h. Clin Cancer Res. 2024 Feb 16;30(4):836-848. doi: 10.1158/1078-0432.CCR-23-2693. Clin Cancer Res. 2024. PMID: 38060240 Free PMC article.
SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis-Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate Cancer.
Swami U, Graf RP, Nussenzveig RH, Fisher V, Tukachinsky H, Schrock AB, Li G, Ross JS, Sayegh N, Tripathi N, Mathew Thomas V, Oxnard GR, Antonarakis ES, Agarwal N. Swami U, et al. Among authors: tukachinsky h. Clin Cancer Res. 2022 Nov 14;28(22):4917-4925. doi: 10.1158/1078-0432.CCR-22-2228. Clin Cancer Res. 2022. PMID: 36088616
Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB.
He J, Kalinava N, Doshi P, Pavlick DC, Albacker LA, Ebot EM, Tukachinsky H, Pratt J, Fusaro G, Oxnard GR, Green G, Fabrizio D, Baden J. He J, et al. Among authors: tukachinsky h. J Immunother Cancer. 2023 Nov 30;11(11):e007339. doi: 10.1136/jitc-2023-007339. J Immunother Cancer. 2023. PMID: 38035725 Free PMC article. Clinical Trial.
Predictive Genomic Biomarkers of Hormonal Therapy Versus Chemotherapy Benefit in Metastatic Castration-resistant Prostate Cancer.
Graf RP, Fisher V, Mateo J, Gjoerup OV, Madison RW, Raskina K, Tukachinsky H, Creeden J, Cunningham R, Huang RSP, Mata DA, Ross JS, Oxnard GR, Venstrom JM, Zurita AJ. Graf RP, et al. Among authors: tukachinsky h. Eur Urol. 2022 Jan;81(1):37-47. doi: 10.1016/j.eururo.2021.09.030. Epub 2021 Oct 26. Eur Urol. 2022. PMID: 34716049 Free article.
29 results